Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.83 |
| ▸ | PPARA | Q07869 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034823 | 0.99 | PPARG (0.81) | PPARGPPARAKDM4EMEN1APOBEC3A | |
| SCHEMBL7040522 | 0.91 | PPARG (0.82) | PPARGPPARAKDM4EMEN1APOBEC3A | |
| SCHEMBL7037316 | 0.91 | PPARG (0.80) | PPARGPPARAKDM4EMEN1APOBEC3A | |
| Lithium Ion SCHEMBL7034820 | 0.91 | PPARG (1.00) | PPARGPPARAKDM4EMEN1APOBEC3A | |
| SCHEMBL7036649 | 0.90 | PPARG (0.80) | PPARGPPARAKDM4EMEN1APOBEC3A | |
| SCHEMBL7035460 | 0.83 | PPARG (0.62) | PPARGPPARANPC1RAB9ASERPINE1 | |
| SCHEMBL7040809 | 0.83 | PPARG (0.83) | PPARGPPARANPC1SERPINE1TP53 | |
| SCHEMBL7033982 | 0.82 | PPARG (0.61) | PPARGPPARANPC1RAB9ASERPINE1 | |
| SCHEMBL7039964 | 0.82 | PPARG (0.81) | PPARGPPARANPC1SERPINE1TP53 | |
| Lithium Ion SCHEMBL7036645 | 0.82 | PPARG (1.00) | PPARGPPARAKDM4EMEN1APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | claimed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | claimed |
| WO-2017044551-A1 | PPAR-ALPHA AGONISTS FOR TREATING MITOCHONDRIAL DISEASES | MITOBRIDGE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885KDM4E 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.